Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major dry age macular degeneration markets are expected to exhibit a CAGR of 4.64% during 2024-2034.

The dry age macular degeneration market has been comprehensively analyzed in IMARC's new report titled "Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dry age macular degeneration is a common eye disorder that mostly affects indiviuals upon aging. This condition causes thinning of the macula's inner layers, which are responsible for detail perception as well as central and color visions. In most cases, vision may deteriorate over time and impair one's ability to drive, read, and recognize faces. Individuals suffering from this ailment may experience a need for brighter light when reading or doing close work, blank or dark spots in the field of vision, increased difficulty adapting to low light levels, straight lines looking crooked or wavy, blurred or diminished central vision, etc. The diagnosis of dry age macular degeneration typically requires a review of the patient's symptoms, medical history, and dilated eye examination. During an eye workup, the healthcare provider will evaluate characteristic changes or abnormalities in the retina and macula, such as the presence of small yellowish deposits called drusen. Numerous other tests to assess visual function, including fluorescein angiography and optical coherence tomography, are also recommended to diagnose dry age macular degeneration.

The expanding geriatric population, who are more susceptible to the degradation of cells in the macula, thereby resulting in scarring of the retina, is primarily driving the dry age macular degeneration market. Additionally, the increasing prevalence of several associated risk factors, such as smoking, obesity, high blood pressure, an inadequate diet, etc., is also propelling the market growth. Moreover, the widespread demand for antioxidant vitamins and minerals, including vitamin C and E, beta-carotene, zinc, copper, etc., which reduce cellular damage by deactivating free radicals in the retina, is further creating a positive outlook for the market. Apart from this, the escalating adoption of anti-angiogenic drugs, such as ranibizumab and aflibercept, that can be directly injected into the eye to help slow the progression of abnormal blood vessels and provide symptom relief is acting as another significant growth-inducing factor. Furthermore, the rising utilization of laser photocoagulation therapy owing to its various advantages, including resolution of drusen, prevention of vision loss, and improvement in quality of life for affected people, is expected to drive the dry age macular degeneration market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the dry age macular degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dry age macular degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dry age macular degeneration market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dry age macular degeneration market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dry age macular degeneration market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dry age macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the dry age macular degeneration market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dry age macular degeneration market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dry age macular degeneration market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of dry age macular degeneration across the seven major markets?
What is the number of prevalent cases (2018-2034) of dry age macular degeneration by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dry age macular degeneration by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with dry age macular degeneration across the seven major markets?
What is the size of the dry age macular degeneration patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dry age macular degeneration?
What will be the growth rate of patients across the seven major markets?

Dry Age Macular Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dry age macular degeneration drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dry age macular degeneration market?
What are the key regulatory events related to the dry age macular degeneration market?
What is the structure of clinical trial landscape by status related to the dry age macular degeneration market?
What is the structure of clinical trial landscape by phase related to the dry age macular degeneration market?
What is the structure of clinical trial landscape by route of administration related to the dry age macular degeneration market?